Anti-CD20 (rituximab) treatment for atopic eczema.
Sedivá
Anna
A
Kayserová
Jana
J
Vernerová
Eva
E
Poloucková
Andrea
A
Capková
Stepánka
S
Spísek
Radek
R
Bartůnková
Jirina
J
D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000187:drug effects; D003713:Dendritic Cells / Q000187:drug effects; D003876:Dermatitis, Atopic / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D004804:Eosinophils / Q000187:drug effects; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood / Q000187:drug effects; D010950:Plasma Cells / Q000187:drug effects; D000069283:Rituximab; D013601:T-Lymphocytes / Q000187:drug effects
D018926:Anti-Allergic Agents; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D007073:Immunoglobulin E; D000069283:Rituximab